Drugs that contain Ranolazine
1. Aspruzyo Sprinkle patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11510878 | SPIL | Extended release multiparticulates of ranolazine |
Jan, 2038
(13 years from now) | |
| US10898444 | SPIL | Extended release multiparticulates of ranolazine |
Jan, 2038
(13 years from now) | |
Market Authorisation Date: 28 February, 2022
Treatment: NA
Dosage: GRANULES, EXTENDED RELEASE;ORAL
More Information on Dosage
ASPRUZYO SPRINKLE family patents
2. Ranexa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6369062 | MENARINI INTL | Sustained release ranolazine formulations |
May, 2019
(4 years ago) | |
| US6503911 | MENARINI INTL | Sustained release ranolazine formulations |
May, 2019
(4 years ago) | |
| US6303607 | MENARINI INTL | Method for administering a sustained release ranolanolazine formulation |
May, 2019
(4 years ago) | |
| US6852724 | MENARINI INTL | Sustained release ranolazine formulations |
May, 2019
(4 years ago) | |
| US6620814 | MENARINI INTL | Sustained release ranolazine formulations |
May, 2019
(4 years ago) | |
| US6617328 | MENARINI INTL | Sustained release ranolazine formulations |
May, 2019
(4 years ago) | |
| US6479496 | MENARINI INTL | Methods for treating angina with ranolazine |
May, 2019
(4 years ago) | |
| US6525057 | MENARINI INTL | Sustained release ranolazine formulations |
May, 2019
(4 years ago) | |
| US6864258 | MENARINI INTL | Sustained release ranolazine formulations |
May, 2019
(4 years ago) | |
| US6562826 | MENARINI INTL | Sustained release ranolazine formulations |
May, 2019
(4 years ago) | |
Market Authorisation Date: 12 February, 2007
Treatment: Treating chronic angina by administering an extended release form of ranolazine
Dosage: TABLET, EXTENDED RELEASE;ORAL
How can I launch a generic of RANEXA before it's drug patent expiration?
More Information on Dosage
RANEXA family patents